Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/giant-biogene-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:35950:1" rel="noopener">Giant Biogene Holding (GBH HK)</a>  aims to raise around US$500m in its Hong Kong IPO.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>We had looked at the company’s past performance in our previous notes. In this note, we’ll undertake a peer comparison.</li>
</ul>



Giant Biogene Holding (GBH HK)  aims to raise around US$500m in its Hong Kong IPO.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
We had looked at the company’s past performance in our previous notes. In this note, we’ll undertake a peer comparison.


Giant Biogene Pre-IPO - Peer Comparison - Might Need to Spend a Lot More Online

<ul>
<li>
<a href="https://www.smartkarma.com/entities/giant-biogene-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:35950:1" rel="noopener">Giant Biogene Holding (GBH HK)</a> aims to raise around US$500m in its Hong Kong IPO.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>We had looked at the company’s past performance in  our previous notes. In this note, we’ll talk about its PHIP updates.</li>
</ul>



Giant Biogene Holding (GBH HK) aims to raise around US$500m in its Hong Kong IPO.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
We had looked at the company’s past performance in  our previous notes. In this note, we’ll talk about its PHIP updates.


Giant Biogene Pre-IPO - PHIP Updates - Sales Growing Faster but so Have Marketing Spends

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Estee Lauder Companies Cl A / Equity Bottom-Up

<ul><li>Estee Lauder delivered an organic sales growth of 8% and managed to surpass Wall Street expectations in terms of revenues as well as earnings.</li><li>Although Covid-19 in the Asia Pacific in the fourth quarter put a lot of pressure on sales, 9 of the company’s brands contributed double-digit organic sales growth for the year.</li><li>Estee Lauder continued to diversify in high-growth channels globally during the year to increase their consumer reach.</li></ul>

Estee Lauder delivered an organic sales growth of 8% and managed to surpass Wall Street expectations in terms of revenues as well as earnings.Although Covid-19 in the Asia Pacific in the fourth quarter put a lot of pressure on sales, 9 of the company’s brands contributed double-digit organic sales growth for the year.Estee Lauder continued to diversify in high-growth channels globally during the year to increase their consumer reach.

Estee Lauder Companies Inc: Digital Acceleration & Other Drivers

Japan Specialist

Mark Chadwick

<ul>
<li>Chinese lockdowns are taking their toll on Q2 sales. We expect the upcoming report to be much worse than the last </li>
<li>Estee Lauder's recent results suggest that travel retail will be a negative shock too </li>
<li>We believe there is one large downgrade to full-year guidance and consensus numbers. Too early turn bullish </li>
</ul>


Chinese lockdowns are taking their toll on Q2 sales. We expect the upcoming report to be much worse than the last 
Estee Lauder's recent results suggest that travel retail will be a negative shock too 
We believe there is one large downgrade to full-year guidance and consensus numbers. Too early turn bullish 


Shiseido (4911 JP) | Q2 Results Will Make Analysts Blush

Estee Lauder Companies Cl A / Equity Capital Markets

<ul><li>Despite the increase of the temporary Covid-19 restriction in China, Estee Lauder managed to delivere an organic sales growth of 9% in the third quarter of the fiscal year 2022.</li><li>As volatility increased, the company maintained cost discipline and expanded its operating margin, resulting in higher-than-expected adjusted diluted earnings-per-share growth of 17%.</li><li>Eleven brands grew organically by double digits in the quarter which was a positive sign for Estee Lauder.</li></ul>

Despite the increase of the temporary Covid-19 restriction in China, Estee Lauder managed to delivere an organic sales growth of 9% in the third quarter of the fiscal year 2022.As volatility increased, the company maintained cost discipline and expanded its operating margin, resulting in higher-than-expected adjusted diluted earnings-per-share growth of 17%.Eleven brands grew organically by double digits in the quarter which was a positive sign for Estee Lauder.

Estee Lauder Companies Inc.: Competitive Positioning & Growth Drivers

United States

The Estee Lauder Companies Inc. manufactures and markets a wide range of skin care, makeup, fragrance, and hair care products.  The Company's products are sold in countries and territories around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Estee Lauder Companies Cl A (EL US)

Giant Biogene Pre-IPO - Peer Comparison - Might Need to Spend a Lot More Online

Giant Biogene Holding aims to raise around US$500m in its Hong Kong IPO. In this note, we will undertake a peer comparison.

Sumeet Singh

Giant Biogene Pre-IPO - PHIP Updates - Sales Growing Faster but so Have Marketing Spends

Giant Biogene aims to raise around US$500m in its Hong Kong IPO. The company is one of the leaders in the bioactive ingredient-based professional...

Sumeet Singh

Estee Lauder Companies Inc: Digital Acceleration & Other Drivers

Estee Lauder delivered an organic sales growth of 8% and managed to surpass Wall Street expectations in terms of revenues as well as...

Baptista Research

Shiseido (4911 JP) | Q2 Results Will Make Analysts Blush

We believe that Shiseido faces significant headwinds in the current quarter. We expect a large downward revision to company guidance and street...

Mark Chadwick

Estee Lauder Companies Inc.: Competitive Positioning & Growth Drivers

Despite the increase of the temporary Covid-19 restriction in China, Estee Lauder managed to delivere an organic sales growth of 9% in the third...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)